{"id":10538,"date":"2025-11-13T09:26:08","date_gmt":"2025-11-13T08:26:08","guid":{"rendered":"https:\/\/ep-ad.org\/?p=10538"},"modified":"2026-01-26T09:35:10","modified_gmt":"2026-01-26T08:35:10","slug":"journal-of-alzheimers-disease-2","status":"publish","type":"post","link":"https:\/\/ep-ad.org\/index.php\/2025\/11\/13\/journal-of-alzheimers-disease-2\/","title":{"rendered":"Journal of Alzheimer\u2019s Disease"},"content":{"rendered":"\n<p>\u201cAssociations of lifestyle factors with amyloid pathology in persons without dementia\u201d<\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/ep-ad.org\/wp-content\/uploads\/2015\/05\/Logo-EPAD-e1442819956731-1.png\" alt=\"This image has an empty alt attribute; its file name is Logo-EPAD-e1442819956731-1.png\"\/><\/figure>\n\n\n\n<p><strong>Authors:<\/strong> Julie E.&nbsp;Oomens et al, for the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI); A4 Study group; Dominantly Inherited Alzheimer Network (DIAN); European Prevention of Alzheimer&#8217;s Dementia (EPAD) consortium, Fundaci\u00f3 ACE Healthy Brain Initiative (FACEHBI); Japan Alzheimer&#8217;s Disease Neuroimaging Initiative (J-ADNI), Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer&#8217;s Disease (KBASE); Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer&#8217;s Disease (PREVENT-AD)<\/p>\n\n\n\n<p><strong>Abstract:<\/strong><\/p>\n\n\n\n<p>Background: The association between lifestyle factors and Alzheimer&#8217;s disease (AD) pathophysiology remains incompletely understood.<\/p>\n\n\n\n<p>Objective: The aim of this study was to assess the association of alcohol consumption, smoking behavior, sleep quality and physical, cognitive, and social activity with cerebral amyloid pathology.<\/p>\n\n\n\n<p>Methods: For this cross-sectional study, we selected participants from the Amyloid Biomarker Study data pooling initiative. We used generalized estimating equations to assess associations of dichotomized lifestyle measures with amyloid pathology.<\/p>\n\n\n\n<p>Results: We included 9171 participants with normal cognition (NC) and 2555 participants with mild cognitive impairment (MCI) from the Amyloid Biomarker Study. Of participants with NC, 58% were women, 34% were <em>APOE<\/em> \u03b54 carrier, and 27% had amyloid pathology. Of participants with MCI, 48% were women, 47% were <em>APOE<\/em> \u03b54 carrier, and 57% had amyloid pathology. In NC, cognitively active participants were less likely to have amyloid pathology (OR\u2009=\u20090.77, 95%CI 0.66\u20130.89, p\u2009&lt;\u20090.001). In MCI, participants who had ever smoked or had sleep problems were less likely to have amyloid pathology (OR\u2009=\u20090.85, 95%CI 0.73\u20130.99, p\u2009=\u20090.029; OR\u2009=\u20090.62, 95%CI 0.45\u20130.86, p\u2009=\u20090.004).<\/p>\n\n\n\n<p>Concluaions: In NC, cognitive activity was associated with a lower frequency of amyloid pathology. In MCI, favorable lifestyle behaviors were not associated with a lower frequency of amyloid pathology. The results of the current study contribute to the broader evidence base on lifestyle and AD by further characterizing the role of lifestyle behaviors in AD pathology across different clinical stages.<\/p>\n\n\n\n<p><strong>DOI<\/strong>: <a href=\"https:\/\/journals.sagepub.com\/toc\/alza\/108\/3\"><\/a><a href=\"https:\/\/doi.org\/10.1177\/13872877251379083\">https:\/\/doi.org\/10.1177\/13872877251379083<\/a><\/p>\n\n\n\n<p>Published online:&nbsp;13 November 2025 in the journal of Alzheimer&#8217;s disease<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u201cAssociations of lifestyle factors with amyloid pathology in persons without dementia\u201d Authors: Julie E.&nbsp;Oomens et al, for the Alzheimer&#8217;s Disease Neuroimaging Initiative (ADNI); A4 Study group; Dominantly Inherited Alzheimer Network (DIAN); European Prevention of Alzheimer&#8217;s Dementia (EPAD) consortium, Fundaci\u00f3 ACE Healthy Brain Initiative (FACEHBI); Japan Alzheimer&#8217;s Disease Neuroimaging Initiative (J-ADNI), Korean Brain Aging Study for [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"class_list":["post-10538","post","type-post","status-publish","format-standard","hentry","category-publications"],"_links":{"self":[{"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/posts\/10538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/comments?post=10538"}],"version-history":[{"count":4,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/posts\/10538\/revisions"}],"predecessor-version":[{"id":10545,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/posts\/10538\/revisions\/10545"}],"wp:attachment":[{"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/media?parent=10538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/categories?post=10538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ep-ad.org\/index.php\/wp-json\/wp\/v2\/tags?post=10538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}